AI researchers set sights on detecting COVID-19 in imaging results

Researchers are hard at work developing new AI algorithms that could help radiologists diagnose COVID-19 patients.

The study, a collaboration between the University of Chicago and Argonne National Laboratory, received funding from the newly established C3.ai Digital Transformation Institute.

The goal is to develop AI tools that can assess chest x-rays and thoracic CT scans, helping specialists detect signs of COVID-19 and even determine which stage of the infection the patient is experiencing. Researchers also hope to identify COVID-19 cases completely missed by other means of detection. Giger’s team has previous experience developing models that can spot signs of emphysema, heart disease and osteoporosis.

“We’re taking our AI development knowledge that we’ve learned from analyzing other lung diseases and using it here,” Maryellen Giger, PhD, a professor of radiology at the University of Chicago, said in a news release on the school’s website. “In doing so, we will conduct transfer learning and get away with a lot fewer cases as we combine medical imaging intelligence with machine intelligence.”

Giger noted that such research is especially important because it is unclear how long this ongoing pandemic will last.

“The impact of this research area is expected to be great because, as we move into a potential next wave or if COVID is looked at as a chronic disease, we will need to be able to recognize it,” she said in the same news release. “One of the ways of doing that is through what's routinely obtained: chest radiographs and low dose CTs for lung screening. So this will just be another checkbox of ‘is there COVID potential here?’”

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.